摘要
探讨保尔佳在复发性中、高度恶性非霍奇金淋巴瘤再化疗中的使用效果。选取有明确病理诊断且既往用过ＣＨＯＰ方案化疗的复发性非霍奇金淋巴瘤共４８例，随机分为两组，治疗组再次启用ＣＨＯＰ方案化疗，并在化疗前５天开始加用保尔佳针剂３０μｇ肌肉注射，１次／日×２０日，对照组应用ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案，分别评定近期疗效、毒副反应、Ｔ细胞亚群分布状态。治疗组ＣＲ率达３７．５％，对照组为５０．０％，差异无显著性（Ｐ＞０．０５）；两组共有的毒副反应为骨髓抑制、消化道反应及心肌毒性，均能耐受。但治疗组Ⅲ度以上消化道反应低于对照组（Ｐ＜０．０５）；治疗组化疗后Ｔ细胞亚群中ＣＤ＋３、ＣＤ＋４水平明显高于对照组（Ｐ＜０．０１）。保尔佳在复发的ＮＨＬ再化疗中有明显的增敏作用。
To evaluate the effect of Polyerga in re chemotherapy of recurrent intermediate and high malignant non Hodgkin's lymphoma (NHL). Forty eight recurrent NHL patients who were confirmed pathologically and had previous CHOP protocol therapy were divided randomly into two arms. Patients in arm A CHOP protocol and Polyerga 30μg IM/qd starting 5 days prior to the chemotherapy for 20 days were given.Those in the arm B received ProMACE CytaBOM regimens. The short term therapeutic effects, toxic side effects of the patients with stress on T cell subset distribution.The CR in arms A+B were 37.5% and 50.0% ( P >0.05) respectively with no statistically significance. The toxic side effects in both groups were tolerable bone marrow suppression,gastroenteric reaction and myocardial toxicity, however, grade III GI reaction was lower in arm A than in the arm B ( P <0.05). After treatment, the levels of CD 3 and CD 4 in T cell subgroup were obviously higher in arm A than in arm B( P <0.01). Polyerga remarkably render the patients more ameuable repeated chemotherapy and being enhanced in cell immune function.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1998年第6期465-467,共3页
Chinese Journal of Clinical Oncology
关键词
保尔佳
淋巴瘤
药物疗法
NHL
Polyerga Recurrent non Hodgkins lymphoma Drug therapy
